Melanoma oncologist interested in novel immunotherapy and phase I trials
Boston, MA
Joined June 2019
- Tweets36
- Following84
- Followers192
- Likes94
elizabeth buchbinder retweeted
New #JITC article: Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab bit.ly/3MrU0O4 @ta_sussman @annwsilkmd @rhaq1 @bbuchbinderMD
elizabeth buchbinder retweeted
SITC thanks Drs. Pavlick & Sullivan and all members of our SITC Melanoma Immunotherapy Guideline Expert Panel for their efforts in developing this clinical practice guideline. @bbuchbinderMD @OmidHamidMD @TJH0828 @KeithTolley
#SITCGuidelines #melanoma #skincancer
elizabeth buchbinder retweeted
Update in #melanoma #TIL news: lifileucel PDUFA date pushed back to Feb 2024 due to delays on the @FDAOncology end. This isn’t a problem with the data etc.
This is a huge hit to patients desperately waiting for this lifesaving treatment. We already have waitlists and now there are minimal options. Patients simply can’t wait this long. @MelanomaReAlli @AIMatMelanoma @CureMelanoma @ASTCT @OmidHamidMD @HaanenJohn @bbuchbinderMD @drkomanduri @alexshoushtari @jsmithymd
ir.iovance.com/news-releases… – at West Menlo Park, CA
elizabeth buchbinder retweeted
Good morning from Women in Melanoma 🌞
Emily Tonirezos @theNCI kicking off the agenda talking about the definition of cancer survivor, so well worded:
An individual is considered a cancer survivor from the time of diagnosis through the balance of life
#WIM23 @AIMatMelanoma
elizabeth buchbinder retweeted
Engaged and leaning in for this talk @AIMatMelanoma #WIM meeting on “Disenfranchised grief” by @MollyVocino from @TJUHospital @KimmelCancerCtr Trajectory of #grief, grief v trauma, over-pathologizing grief
elizabeth buchbinder retweeted
Forget your sunscreen? Mass General Brigham has got you covered 🧴🧴🧴@IMPACTMelanoma
elizabeth buchbinder retweeted
Wonderful tribute to Val Guild who transformed melanoma care, research and delivery by @jmkirkwood and Thach Giao at the @eaonc and @SWOG social. @AIMatMelanoma
elizabeth buchbinder retweeted
Adjuvant pembro in stage IIB/C melanoma from Keynote-716 by @ProfGLongMIA with statistically significant DMFS difference at 2 years - 88.1 v 82.2
RFS widened a smidge at 2 yrs
Conclusion? stage II adjuvant conversation still a tough one
#ASCO22
Join me on Jan. 27, for the @sitcancer #LearnACI live virtual Intratumoral Therapies, Vaccines and Cytokines program featuring in-depth education on all aspects of clinical implementation of immunotherapy. Register today and invite a colleague: sitcancer.org/education/aci/…
elizabeth buchbinder retweeted
Head to head comparison of triple therapy trial outcomes in #melanoma from Zeynep Eroglu @MoffittNews
Other relevant mPFS comparators noted by @YanaNajjarMD:
-ipi/nivo 16.8m (Checkmate 067)
-enco/bini 14.9m (COLUMBUS)
#WomenInMelanoma @AIMatMelanoma
#WomenInMedicine
So wonderful to discuss melanoma with such an amazing group of women. @AIMatMelanoma – at Wellesley, MA
To kick off @AIMatMelanoma Women in Melanoma 2020, the incredible @AshaniTW is dropping some knowledge on the addictiveness of tanning and the effects of age on tumor microenvironment in melanoma! Ashi, so great to have you as part of the conference this year!
elizabeth buchbinder retweeted
Bravo @ASCO @ASCOPost for profiling a #mentor #leader #brother @Stevenhodi @DanaFarber a roadmap to contributing and educating. Dr. Hodi has lead the combination of Immunotherapeutics since his groundbreaking Ipi-avastin trials. – at Los Angeles, CA
elizabeth buchbinder retweeted
In case you are wondering about IL-6 inhibitor Tociluzumab effect in #COVID19 serious infections: N=20. 19/20 discharged in 2 weeks. Improvement in lung lesions. Reduction in fever/C-reactive protein, increase O2 saturation among others.
LINK to paper chinaxiv.org/abs/202003.0002…
elizabeth buchbinder retweeted
I have blown my cover...it now has to be a stealth mission to capture them. Stay tuned.
elizabeth buchbinder retweeted
#COVID19 Bar Chart from 3/1 to 3/22 worldwide – at Westwood, MA
elizabeth buchbinder retweeted
Dr. Mike Davies @MDAndersonNews and colleagues present interesting prelim data for OXPHOSi in prevention/treatment of melanoma brain metastases... area of huge unmet need
Fantastic talk by Megan Insco about CDK13 mutations in melanoma. @SocietyMelanoma – at Salt Lake City, UT
elizabeth buchbinder retweeted
Great talk on #womeninscience & #WomenInSTEM from CEO of @huntsmancancer. Her tips on professional joy below! @SocietyMelanoma congress.
elizabeth buchbinder retweeted
In high school, girls have more credits and better GPA in math and science; but are more likely to leave STEM fields and are under-represented in leadership roles in academia. @DrBetofMDPhD @mcquadeMDLAc @RieWeb20 on stage with Dr. Beckerle.
elizabeth buchbinder retweeted
Beyond excited for @SocietyMelanoma meeting In Salt Lake City. Please don't miss the Women in Science session on Thursday at 2 pm. I will be co-facilitating a group meeting on Negotiations, Hiring and Promotions with @sloan_kettering 's Paul Chapman.